RxDoctor Payments Data

Vamshi Mallavarapu, MD

Cardiovascular Disease · Horsham, PANPI 1992864474

Payments from drug & device makers

$4,477in general payments, 2019–2025

Across 90 payments — averaging $49.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$516
  • Medtronic$418
  • Novartis$372
  • Johnson & Johnson$265
  • Esperion Therapeutics, Inc.$237
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,472100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,477 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,058,262
Medicare patients
4,715
Services billed
11,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban722$656,980
EntrestoSacubitril/Valsartan175$191,962
XareltoRivaroxaban183$154,311
Repatha SureclickEvolocumab66$55,197
JardianceEmpagliflozin66$43,448
NexlizetBempedoic Acid/Ezetimibe40$20,729
Praluent PenAlirocumab13$10,716
FarxigaDapagliflozin Propanediol12$8,519
Atorvastatin Calcium524$7,779
Flecainide Acetate147$6,068
Diltiazem 24hr Er (Cd)Diltiazem Hcl225$5,778
Metoprolol Succinate303$4,342
Carvedilol337$3,490
Losartan Potassium288$2,767
Rosuvastatin Calcium205$2,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$656,980722 claims
NovartisEntresto$372$191,962175 claims
Johnson & JohnsonXarelto$265$154,311183 claims
Boehringer IngelheimJardiance$124$43,44866 claims
Esperion Therapeutics, Inc.Nexlizet$237$20,72940 claims
AstraZenecaFarxiga$108$8,51912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Horsham

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →